BridgeBio Oncology Therapeutics (BBOT) Research & Development (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Research & Development of $39.8 million for Q1 2026, up 4.54% sequentially from $38.1 million in Q4 2025, and up 92.89% YoY from $20.6 million in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Research & Development (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Research & Development for 3 years, with the latest figure at $39.8 million in Q1 2026.
- Quarterly Research & Development rose 92.89% year-over-year to $39.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $133.6 million (changed N/A YoY) and the FY2025 annual result came in at $121.2 million, up 65.78% from the prior year.
- Research & Development climbed to $39.8 million in Q1 2026 per BBOT's latest filing, from $38.1 million in the prior quarter.
- Over five years, Research & Development peaked at $39.8 million in Q1 2026 and troughed at $17.9 million in Q3 2024.
- A 3-year average of $28.5 million and a median of $27.8 million in 2025 frame the typical range for Research & Development.
- The sharpest annual moves came in 2025 and 2026: Research & Development surged 95.94% in 2025, then surged 92.89% in 2026.
- Over 3 years, Research & Development stood at $19.5 million in 2024, then soared by 94.85% to $38.1 million in 2025, then increased by 4.54% to $39.8 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $39.8 million, $38.1 million, and $35.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 49.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.23 Mn |
| Mar 31, 2026 | 39.80 Mn |
| Dec 31, 2025 | 38.07 Mn |
| Sep 30, 2025 | 35.05 Mn |
| Mar 31, 2025 | 20.64 Mn |
| Dec 31, 2024 | 19.54 Mn |
| Sep 30, 2024 | 17.89 Mn |